TXMD · TherapeuticsMD, Inc. · Webcasts, Transcripts & Audio
$1.79
-0.04 (-1.92%)
At close · Nov 5
View the 10-Q filed Aug 11, 2026
Return incl. dividend (before tax)
Q2 2022 earnings call transcript
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The potential impact of these factors in conjunction with the uncertainty of the capital markets raises substantial doubt about our ability to continue as a going concern for the next twelve months from the issuance of these financial statements.”View the 10-Q filed Aug 11, 2026
Customer concentration
— top 3 customers 100% of revenue
3 customers — 100% of revenue (the three and six months ended June 30, 2026)
“For the three and six months ended June 30, 2026, 100% of license revenue related to Mayne Pharma, Theramex and Knight.”
Market Cap
$21.07M
Shares
11.57M
Volume · Nov 5
2911
Avg daily vol (3M)
23.41K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
TherapeuticsMD, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for TherapeuticsMD, Inc. (TXMD), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY22 · Q3
2022-11-14
TherapeuticsMD, Inc. (TXMD) Q3 2022 Earnings Call
Revenue
$354,000
▼ 98.6% YoY Diluted EPS
$-3.13
Gross margin
0.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-15
TherapeuticsMD, Inc. (TXMD) Q2 2022 Earnings Call Transcript
Revenue
$348,000
▼ 98.5% YoY Diluted EPS
$12.83
Gross margin
0.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-16
TherapeuticsMD, Inc. (TXMD) Q1 2022 Earnings Call Transcript
Revenue
$695,000
▼ 96.5% YoY Diluted EPS
$-5.70
Gross margin
2082.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-10
TherapeuticsMD, Inc. (TXMD) Q4 2021 Earnings Call Transcript
Revenue
$18.68M
▼ 17.3% YoY Gross margin
74.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-11
TherapeuticsMD, Inc. (TXMD) Q3 2021 Earnings Call Transcript
Revenue
$25.41M
▲ 31.4% YoY Diluted EPS
$-5.62
Gross margin
79.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-04
TherapeuticsMD, Inc. (TXMD) Q2 2021 Earnings Call Transcript
Revenue
$23.00M
▲ 114.9% YoY Diluted EPS
$-5.41
Gross margin
82.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
TherapeuticsMD, Inc. (TXMD) Q1 2021 Earnings Call Transcript
Revenue
$19.87M
▲ 62.2% YoY Gross margin
76.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-02
TherapeuticsMD, Inc. (TXMD) Q4 2020 Earnings Call Transcript
Revenue
$22.58M
▲ 42% YoY Gross margin
75.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-09
TherapeuticsMD, Inc. (TXMD) Q3 2020 Earnings Call Transcript
Revenue
$19.34M
▼ 18.5% YoY Gross margin
83.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
TherapeuticsMD, Inc. (TXMD) Q2 2020 Earnings Call Transcript
Revenue
$10.70M
▲ 76% YoY Gross margin
58.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-06
TherapeuticsMD, Inc. (TXMD) Q1 2020 Earnings Call Transcript
Revenue
$12.25M
▲ 210.4% YoY Gross margin
77.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-20
TherapeuticsMD, Inc. (TXMD) Q4 2019 Earnings Call
Revenue
$15.90M
▲ 212.5% YoY Gross margin
81.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–12 of 12 webcasts